Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2012

View Archived Issues

FX-006 achieves prolonged therapeutic concentrations in osteoarthritis

ViiV Healthcare files for approval of dolutegravir

Bioengineering of a human lung-on-a-chip model for drug efficacy and toxicity screening

ALKS-5461 as a novel combination therapy for the treatment of cocaine abuse

Scientists at the Wistar Institute prepare new vaccines for influenza A

MacroGenics discloses novel diabodies for the treatment of cancer

University of Georgia patents new antiviral prodrugs

Array BioPharma prepares new Trk-A inhibitors

Merck & Co. synthesizes novel M1 receptor positive allosteric modulators

Genentech presents two antibody-drug conjugates for the treatment of NHL

Mechanisms for improving blood cell count following hematopoietic progenitor cell transplant

Researchers at institutes in California present new protein kinase inhibitors

Preclinical studies validate Immuron's Clostridium therapeutic

EyeGate Pharma enrolls last patient in phase III EGP-437 trial

La Jolla Pharmaceutical reports promising results from preclinical GCS-100 study

Acasti Pharma updates on CaPre development

In vitro A-1014907 data show promise in multiple myeloma

Lorus Therapeutics and Brock University to develop novel anticancer drugs

GlaxoSmithKline and Theravance submit NDA for umeclidinium bromide/vilanterol

Navidea Biopharmaceuticals submits MAA for Lymphoseek to the EMA

Vanda Pharmaceuticals reports phase III data for the circadian regulator tasimelteon

Actelion's ponesimod trial meets primary endpoint in psoriasis

Tranzyme Pharma stops DIGEST trial of TZP-102 due to insufficient efficacy

Interim safety results reported from phase IIa study of stem cell therapy in RA

Co-development agreement reached for NTCell for Parkinson's disease

Shire obtains approval for Elvanse in ADHD under European decentralized procedure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...